Aisling Capital Team

Aisling Capital is led by a group of investment professionals with diverse backgrounds in
industry, science and finance.

The team’s complementary backgrounds give Aisling Capital unique perspective on the key players, events, and forces shaping the life science industry, and allow the Fund to identify investment opportunities. In working with our portfolio companies, the principals of Aisling Capital seek to provide the financing, relationships, and guidance needed to build highly successful companies.

  • Dennis Purcell


    Dennis Purcell

    Mr. Purcell is the original Founder of Aisling Capital LLC. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

    Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.

    Mr. Purcell has served as a director of Aton Pharma (acquired by Merck), Bridge Pharmaceuticals (acquired by Pharmaron), Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. Mr. Purcell also served as a member of the Section Governing Board at BIO (“Biotechology Innovation Organization”), the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the Boards of Real Endpoints, Summus Global, Inc., BioScience Managers, and Ichnos Sciences. He sits on the Editorial Advisory Board at Life Science Leader Magazine; Member of the Board at NYBIO Association; Board Member at The University of Delaware Investment Visiting Committee as well as a member of the Biopharmaceutical Innovation Board at the University of Delaware.

    Mr. Purcell received his M.B.A. from Harvard Business School and his B.S. in Accounting from the University of Delaware.

  • Steven Elms

    Managing Partner

    Steven Elms

    Mr. Elms joined Aisling in 2000 and serves as one of the Managing Partners. Prior to Aisling, he was a Principal in the Life Sciences Investment Banking Group of Chase H&Q (formerly Hambrecht & Quist, “H&Q”). During his five years at H&Q, Mr. Elms was involved in over 60 financing and M&A transactions, helping clients raise in excess of $3.3 billion in capital. Prior to H&Q, Mr. Elms traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories and two years as a consultant for The Wilkerson Group.

    Mr. Elms currently serves as chairman of the board of Adma Biologics and Elevation Oncology; a board member of Marker Therapeutics and Treeline Biosciences; and a board observer of Verona Pharma. His prior board service includes Adams Respiratory Therapeutics (acquired by Reckitt Benckiser), Advion BioSciences (acquired by Bohui Innovation Technology), Ambit Biosciences (acquired by Daiichi-Sankyo), Archimica Cooperatief (acquired by Euticals), Avera Pharmaceuticals, Bioenvision (acquired by Genzyme), CeNeRx BioPharma, Cidara Therapeutics, EarLens, LENSAR, Loxo Oncology (acquired by Eli Lilly), MAP Pharmaceuticals (acquired by Allergan), Medical Knowledge Group (acquired by Novo Holdings),  NextWave Pharmaceuticals (acquired by Pfizer), Novazyme Pharmaceuticals (acquired by Genzyme), Oculex Pharmaceuticals (acquired by Allergan), Pernix Therapeutics, Scerene Healthcare, TRIA Beauty and Zosano Pharma. He also serves on the INVO Board at Northwestern University.

    Mr. Elms received his M.B.A. from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Human Biology from Stanford University.

  • Andrew Schiff, MD

    Managing Partner

    Andrew Schiff, MD

    Dr. Schiff joined Aisling in 2000 and serves as one of the Managing Partners. Prior to Aisling, Dr. Schiff practiced internal medicine for six years at the New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine.

    Dr. Schiff currently serves as a director of Aclaris Therapeutics, Dren Bio, and Monte Rosa Therapeutics. Additionally, Dr. Schiff serves as a board observer of Antios Therapeutics and Prolacta Biosciences. His prior board service includes Adams Respiratory Therapeutics (acquired by Reckitt Benckiser), Agile Therapeutics, ArgiNOx Pharmaceuticals, ARMGO Pharma, Barrier Therapeutics (acquired by Stiefel Laboratories), Bioenvision (acquired by Genzyme), CardioKine (acquired by Cornerstone), Cempra Pharmaceuticals, F2G, Harmony Biosciences, Miramar Labs (acquired by Sientra), Myogen (acquired by Gilead Sciences), PowerVision (acquired by Alcon), Quintiles (now IQVIA), SkinMedica (acquired by Allergan), Sirion Therapeutics (licenses acquired by Alcon), TransEnterix, Zavante Therapeutics (acquired by Nabriva) and ZELTIQ Aesthetics (acquired by Allergan).  He is a longtime supporter and board member of the Visiting Nurse Service of New York.

    Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia Business School, and his B.S. with honors in Neuroscience from Brown University.

  • Dr. J.H. Bilenker

    Operating Partner

    Dr. J.H. Bilenker

    Dr. Bilenker joined Aisling in 2006 and has served as an Operating Partner of Aisling since 2014. He was a full-time employee of Aisling from 2006 and 2014 and served as a Partner from 2012 to 2014. From 2013 until the acquisition of Loxo Oncology (an Aisling portfolio company) by Eli Lilly, Dr. Bilenker served as Loxo’s President and Chief Executive Officer. Prior to Aisling, Dr. Bilenker was a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration for two years. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties.

    Dr. Bilenker is currently the Chief Executive Officer and Co-founder of Treeline Biosciences. He serves as a director of Gossamer Bio and Sana Biotechnology. His prior board service includes Aragon Pharmaceuticals (acquired by J&J), LENSAR, Loxo Oncology (acquired by Eli Lilly), Roka Bioscience, T2 Biosystems, ViewRay, NCCN Foundation, and BioEnterprise.

    Dr. Bilenker received his M.D. from The Johns Hopkins School of Medicine. He received his A.B. from Princeton, awarded summa cum laude in English.

  • Aftab Kherani, MD

    Operating Partner

    Aftab Kherani, MD

    Dr. Kherani joined Aisling in 2008 and serves as an Operating Partner. Prior to Aisling, Dr. Kherani was an Engagement Manager for two years at McKinsey & Company, where he was a member of the Pharmaceutical, Medical Product and Private Equity practices. Prior to McKinsey, Dr. Kherani was a Chief Resident in Surgery at Duke University Medical Center, where he completed his residency in general surgery. He also completed a two-year post-doctoral research fellowship investigating treatments for heart failure and arrhythmia at Columbia University, College of Physicians & Surgeons. While at Columbia, he served as an organ procurement fellow as part of the cardiothoracic transplantation team of New York Presbyterian Hospital.

    Dr. Kherani currently serves as Chief Medical Officer of Ajax Health 2 and 3 as well as Zeus Health.  His current board service includes Cortica, Ablacon, Protaryx, Serpex, Verix Health, Summus, and Duke University School of Medicine. His prior board service includes Ajax Health 1, Arcus Biosciences, Loxo Oncology (acquired by Eli Lilly), Spirox (acquired by Entellus), Syros Pharmaceuticals and TransEnterix.

    Dr. Kherani received his M.D. from Duke University School of Medicine, where he was a Howard Hughes Medical Institute Research Fellowship recipient, and his B.S. in Biology and A.B. in Economics from Duke University, awarded magna cum laude and graduating Phi Beta Kappa.

  • Robert Wenzel

    Chief Financial Officer and Chief Compliance Officer

    Robert Wenzel

    Mr. Wenzel joined Aisling in 2008 and serves as the Chief Financial Officer and Chief Compliance Officer.  Prior to Aisling, he was a Vice President at Lazard Alternative Investments (“Lazard”) where he supervised the financial reporting of several domestic and offshore private equity funds. Prior to Lazard, Mr. Wenzel began his career at Eisner & Lubin, LLP, a midsize public accounting firm where he performed audits and prepared tax reports for a diverse clientele, attaining the role of Senior Accountant.

    Mr. Wenzel received his B.B.A. in Accounting from Baruch College and holds his Certified Public Accountant license in the state of New York. He is also a member of the American Institute of Certified Public Accountants and the New York State Society of Certified Public Accountants.

  • Katie Tansey

    Vice President of Investor Relations and Marketing

    Katie Tansey

    Ms. Tansey joined Aisling in 2020 and serves as Vice President of Investor Relations and Marketing.  In this role, Ms. Tansey manages relationships with over 90 limited partners and is a key contributor to Aisling’s fundraising and marketing efforts.  Prior to Aisling, Ms. Tansey was with GAMCO Investors, a multi-billion dollar investment advisory firm identified by its research driven approach to equity investing. During her ten years at GAMCO, Ms. Tansey worked within their Asset Management and Mutual Funds businesses, collaborating across investment, research and distribution teams to provide advisory services to Institutional and Private Wealth Management clients.

    Ms. Tansey received her B.A. in Economics from The University of Michigan.

  • Scott Braunstein, MD

    Operating Partner

    Scott Braunstein, MD

    Dr. Braunstein has served as an Operating Partner of Aisling since 2015. He was appointed Chief Executive Officer of Marinus Pharmaceuticals in August 2019, executive chairman in February 2019, and has served on the Board since September 2018. Prior to his current leadership role at Marinus, he was Chief Operating Officer and Chief Strategy Officer at Pacira Pharmaceuticals, Inc. From 2002 to 2014, Dr. Braunstein worked as a Healthcare Analyst and Portfolio Manager at J.P. Morgan Asset Management, where he invested in and conducted diligence on a wide variety of pharmaceutical products and product candidates. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as Assistant Clinical Professor at Albert Einstein College of Medicine and Columbia University Medical Center. He completed his training at The New York Hospital-Cornell Medical Center.

    Dr. Braunstein currently serves on the board of Trevana Inc., Caribou Biosciences and Constellation Pharmaceuticals. He previously served as board member of Ziopharm Oncology Inc., Esperion Pharmaceuticals, and Protara Therapeutics Inc.

    Dr. Braunstein received his M.D. from the Albert Einstein College of Medicine and his B.S. from Cornell University.

  • Eric Aguiar, MD


    Eric Aguiar, MD

    Dr. Aguiar joined Aisling in 2016 and serves as a Partner. Prior to Aisling, Dr. Aguiar was a partner at Thomas, McNerney and Partners, a $600 million healthcare-focused venture capital and growth equity fund, from 2007 to 2015. Dr. Aguiar was a Managing Director of HealthCare Ventures, a healthcare venture capital fund, from 2001 to 2007. He was CEO of Genovo, Inc., a biopharmaceutical company that specialized in gene delivery and gene regulation. He was also executive director of TheraTech, Inc. He was a Vice President and Managing Director of Philadelphia Ventures from 1992 to 1997.

    Dr. Aguiar currently serves as a director of BridgeBio Pharma, Invitae, Biomea Fusion and Garuda Therapeutics, and as a board observer of PellePharm. His prior board service includes Amarin, CardioKine, Biohaven (acquired by Pfizer), Eidos (merged with BridgeBio), Metaphore (merged with ActivBiotics), Oriel Therapeutics (acquired by Novartis), SkinMedica, Virdante Pharmaceuticals (acquired by Momenta) and 3-D Pharmaceuticals (acquired by Johnson & Johnson). Dr. Aguiar serves as Emeritus Advisor to Tufts University School of Medicine and is a member of the Council on Foreign Relations.

    Dr. Aguiar received his M.D. with honors from Harvard Medical School and his B.A. with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst.

  • Hannah Wieder


    Hannah Wieder

    Ms. Wieder joined Aisling in 2017 and serves as the Controller. Prior to Aisling, she was an audit manager in the wealth & asset management practice at Ernst & Young, where she focused on private equity. Ms. Wieder also spent six years in the financial services group at CohnReznick, a midsize public accounting firm, where she attained the role of Audit Manager and directed the annual audits of various clients within the financial services industry including private equity funds, fund of funds and management companies.

    Ms. Wieder received her M.S. in accountancy from the Zicklin School of Business at Baruch College and her B.S. in business management and finance from Brooklyn College, awarded magna cum laude. She holds her Certified Public Accountant license in the state of New York and is a member of the American Institute of Certified Public Accountants and the New York State Society of Certified Public Accountants.

  • Sunny Reddy


    Sunny Reddy

    Sunny joined Aisling in 2019 and serves as a Principal. Prior to Aisling, Sunny was an Associate and Analyst at SVB Leerink, a healthcare-specialist investment bank, focusing on biopharma/therapeutics. Prior to SVB Leerink, Sunny was a Quantitative Analyst at Bank of America Merrill Lynch specializing in credit derivative products. He was also a research associate working in oncology drug development prior to his careers in finance and investing.

    Sunny currently serves as a board observer for Forge Biologics, Garuda Therapeutics and Wugen. His prior board service includes Monte Rosa Therapeutics (observer).

    Sunny received his B.S. in Biomedical Engineering from the Georgia Institute of Technology with high honors and was a HOPE and Zell Miller Scholar recipient.

  • Carol Zikopoulos

    Head of Human Resources and Compliance Manager

    Carol Zikopoulos

    Ms. Zikopoulos joined Aisling at its formation in 2000 and currently serves as the Head of Human Resources and Compliance Manager. Previously, she was an Administrative Coordinator in the Life Science Investment Banking Groups at both Chase H&Q and PaineWebber, Inc. Ms. Zikopoulos is involved in the day-to-day administration of the firm which includes Human Resources, IT, facilities, vendor management, as well as assisting with the firm’s compliance program together with the CCO.

  • A.J. Sacks


    A.J. Sacks

    A.J. joined Aisling in 2021 and serves as an Analyst. Prior to Aisling, A.J. was an investment banking Analyst at MTS Health Partners focused on M&A and private financings. A.J. is a graduate of the Roy and Diana Vagelos Program in Life Sciences & Management at the University of Pennsylvania. He holds a B.S. in Economics, with a concentration in Finance, and a B.A. in Biology.

  • Wonpyo Yun


    Wonpyo Yun

    Wonpyo rejoined Aisling in 2022 as a Principal, having previously served as an Analyst from 2016 to 2019. Most recently, Wonpyo was an Investment Director at BridgeBio, where he focused on investing and business development activities. He began his career at Credit Suisse in the Healthcare Investment Banking Group.

    Wonpyo received his M.B.A. from the Stanford Graduate School of Business and his A.B. in Molecular Biology, awarded magna cum laude, from Princeton University, from which he also received a Certificate in Finance.